Optimized lentiviral transfer vectors and uses thereof
AssigneesNovartis AG, The Trustees of the University of Pennsylvania
InventorsVladimir SLEPUSHKIN, Dmitriy LUKASHEV
Life of this patent
Estimating the term…
Loading patent…
AssigneesNovartis AG, The Trustees of the University of Pennsylvania
InventorsVladimir SLEPUSHKIN, Dmitriy LUKASHEV
Estimating the term…
The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.
A lentiviral transfer vector comprising a heterologous nucleic acid sequence and being characterized by at least three of the following features:
5-6. (canceled)
10-12. (canceled)
(canceled)
19-22. (canceled)
25-27. (canceled)
(canceled)
A lentiviral transfer vector comprising, from 5′ to 3′, one or more of the following elements in operable association:
32-35. (canceled)
37-39. (canceled)
(canceled)
Dependencies are inferred from the claim text.